
Exciting news! Today the FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. First approval for giredestrant!! FDA.gov. @OncoAlert @OncBrothers
✓
Exciting news! Today the FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. First approval for giredestrant!! FDA.gov. @OncoAlert @OncBrothers

Delighted to have @Sabesan68 on the latest @ASCO #BytheBook Podcast episode! We discuss moving past individual resilience narratives to preserve professional purpose through systemic, team-based support. #EdBook Listen here! ascopubs.org/do/passion-pers… @OncoAlert

There was a time when treating HER2+ breast cancer was relatively simple. That time is over. And that’s great news! Not long ago, we recommended TCHP for most patients with stage II–III disease, and THP (CLEOPATRA) for those with metastatic disease. Straightforward. Almost one-size-fits-all. Within just a few years, that simplicity is gone. And that’s progress. More opportunities to spare unnecessary toxicity, tailor treatments to patients’ preferences, and move beyond rigid algorithms. To be more doctors. In early-stage disease, options now range from de-escalated THP to intensified regimens such as DB11. In metastatic disease, T-DXd/P has achieved unprecedented PFS (>3 years in the 1L setting!), with novel maintenance strategies (palbociclib or tucatinib) potentially pushing the bar even higher. Meanwhile, biomarkers are finally coming of age, from imaging to tissue and plasma. What an era to be treating HER2+ breast cancer! But more options also mean more complexity. For oncologists, and especially for patients. More knowledge needed, more discussions, more decisions to make. How do we navigate this increasingly complex landscape and choose the right treatment for the right patient? We tried to offer some guidance in our new review recently published in @NatRevClinOncol. Read it here: nature.com/articles/s41571-0… @ValenzaCarmine

Join us!! Great panel. Great discussion! Free on zoom. Register below. @OncoAlert

🤔 What breast cancer data from #ESMO2026 have the biggest opportunity to change practice? Hear it from the experts themselves! @hoperugo @RebeccaDSing @cityofhope @NCCS_SG @myESMO #bcsm #oncology Sign up to read our exclusive recap ➡️: onclive.com/view/breast-canc…

ABC Global Alliance - Panel Discussion on HER2+ Metastatic Breast Cancer @ABCGlobalAll @hoperugo @SandraSwainMD @JavierCortesMD oncodaily.com/societies/abc-…

Happy Diwali from India to all celebrating A time to remember that: Light over darkness Understanding over ignorance Love over intolerance These are the foundations of a healthier, better world. 🪔



Almost every week a patient asks me: no mutation, I eat well, I don’t drink, why did I get #BreastCancer ? Most of the time I don’t have a good answer, and I tell her it is not something she did. This week @JCO_ASCO published a Sister Study paper on forever chemicals. Women with higher #PFOS and #PFOA in blood drawn before diagnosis had more ER-negative breast cancer (HR 1.93 and 1.67). It is a signal, not a cause. 17 PFAS were tested and one looked protective. And breastfeeding lowers PFAS levels and ER-negative risk, so I want to see how that was handled. But it reminds me how much we still don’t know about why. Per- and Polyfluoroalkyl Substance Exposure and Breast Cancer Incidence in the Sister Study | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JCO…


Impact of Neoadjuvant Carboplatin in Early-Stage Triple-Negative Breast Cancer: A Pooled Analysis of the BrighTNess, Cancer and Leukemia Group B 40603 (Alliance), and GeparSixto Clinical Trials ascopubs.org/doi/full/10.120…

Exciting to see so many presentations in print on the day of presentation. For the first time ever - 6 papers in @ESMO_Open. Congratulations to the authors and thanks to @esmo, our editors, and Elsevier for helping this happen!

BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer globenewswire.com/news-relea…

#ESMO26 @PTarantinoMD presents the novel and unique Charisma trial with matched samples starting an ADC then with PD. My take? Resistance is incredibly complex and not due to an isolated pathway. Down reg of receptor target uncommon. @OncoAlert

#ESMO26 ctDNA response predicted long disease control in mHER2+ disease published today in the open access @ESMO_Open could direct stopping therapy earlier in a subset. STOPHER2 ongoing. @OncoAlert